Is Ipamorelin FDA Approved? The Answer Is No

Ipamorelin has never had an approved U.S. drug product. Compounded ipamorelin is different from an FDA-approved product; the formulation is not FDA-approved. Its FDA history is a review of ingredients for pharmacy compounding, not a drug approval.

A licensed provider may still prescribe — that decision is between you and your doctor. The useful questions are what FDA reviewed, what the committee recommended, and what the current records actually say.

Is ipamorelin FDA approved? A nomination is not approval

The story starts with a nomination: a request for FDA to consider an ingredient for its 503A bulks list. That's the list of certain raw drug ingredients for compounding under the patient-specific prescription framework.

FDA's docket records show an LDT Health Solutions submission received November 16, 2018, and a Wells Pharmacy Network submission received December 14, 2020. FDA's briefing introduction for the meeting lists LDT as nominating on behalf of the International Peptide Society. A docket's year isn't necessarily the year a particular submission arrived.

The FDA nominations document marked “Updated September 29, 2023” added ipamorelin acetate to Category 2, the group raising significant safety concerns. That is the documented date, rather than October 2023.

Both nominators withdrew their submissions on September 19, 2024, according to FDA's meeting slides. The FDA document marked “Updated September 27, 2024” records the removal from Category 2. It also records withdrawals for AOD-9604, CJC-1295 and thymosin alpha-1. Selank acetate was removed for a different reason: its nominator meant to nominate another substance.

Removal following withdrawal wasn't a finding that the safety concerns had disappeared. The Category 2 guide explains the terminology.

What FDA's staff reviewed

The October 29, 2024 briefing evaluated two ingredients: ipamorelin free base, the molecule without an added salt, and ipamorelin acetate, its acetate salt form. The nominations weren't consistent about which ingredient they meant, so FDA evaluated both forms on its own initiative; after the nominators withdrew, it chose to present that evaluation to the committee anyway.

Staff considered growth hormone deficiency, where the body makes too little growth hormone, and postoperative ileus, a temporary gut slowdown after surgery. They recommended against adding either ingredient to the list.

Their concerns included impurities and aggregation, meaning peptides — short protein-like chains — clumping together. Those can complicate testing and raise concerns about immune reactions. FDA also found major gaps in evidence for the proposed uses and administration under the skin.

There is a reason ipamorelin attracted attention. Raun and colleagues' 1998 paper described selective growth hormone release in animal experiments. Selective means a more focused hormone response; it doesn't establish a human treatment benefit.

The published 2014 bowel-surgery trial didn't establish a benefit over placebo, the comparison treatment without ipamorelin, on its main or secondary treatment measures. The ipamorelin clinical trial article explains that study. The broader ipamorelin benefits discussion covers the uses people ask about.

October 29, 2024: two ingredients, two votes

The Pharmacy Compounding Advisory Committee, or PCAC, gives FDA advice on compounding questions. Its final meeting minutes record the October 29, 2024 discussion at FDA's White Oak campus.

FDA clinical analyst Katie Park and regulatory official Russell Wesdyk presented the ipamorelin review. James Lavalle and Lee Rosebush spoke during the public hearing for the topic.

The committee voted separately on whether each ingredient should enter the 503A bulks list:

Both recommendations were negative. They were advisory votes, not final regulations and not decisions approving a drug product. Keeping those distinctions clear helps explain why a committee tally and a current FDA table can describe different things.

The CJC-1295 FDA review follows the parallel record for that compound.

What the records say after the vote

As of October 1, 2026, the day this article was written, neither ipamorelin ingredient appears in either final table in 21 CFR 216.23. That regulation contains the substances included on the 503A bulks list and those formally considered and excluded. The committee's recommendation hasn't become an ipamorelin entry in those tables.

FDA's current 503A nominations document, marked “Updated May 14, 2026,” also has no ipamorelin entry in its three interim categories. Withdrawal from that document didn't erase the committee review.

The separate 503B nominations table, marked “Updated March 21, 2025,” still lists ipamorelin acetate in Category 2. Section 503B is the framework for registered outsourcing facilities that compound drugs. A 503A table change doesn't automatically change the 503B table.

These records answer different questions. None turns compounded ipamorelin into an approved drug product.

The relevant developments this summer

As of October 1, 2026, the day this article was written, an FDA warning letter dated August 24, 2026 names a tesamorelin–ipamorelin product sold online among unapproved drugs. FDA pointed to health claims and materials for preparing injections as evidence of intended human use. Laboratory labeling didn't change that assessment. The letter addresses that seller's marketing; it isn't a new PCAC vote.

A prescribed route should make accountability visible: a named reviewing clinician, a licensed U.S. pharmacy and a label identifying the medication. The pharmacy should be able to trace the batch and handle medication questions. There should also be a clear contact for reporting side effects and arranging follow-up. A website label alone supplies none of that care.

As of October 1, 2026, the day this article was written, a journal review published August 11, 2026 reports no human clinical evidence for ipamorelin in muscle, bone or tendon injury recovery or athletic performance. It reviewed existing research; it wasn't a new ipamorelin treatment trial.

What this means for your conversation with a provider

The FDA record leaves a practical discussion about the exact medication, the reason for considering it and the evidence for that purpose. A prescription doesn't fill the research gaps. It gives you a clinician who can explain the reasoning, discuss risks and plan follow-up.

At Promise, a licensed provider reviews every request and not everyone qualifies. The product cards carry the current product and visit information.

As of October 1, 2026, the day this article was written, WADA's 2027 list, effective January 1, 2027, names ipamorelin under S2 as prohibited at all times; the 2027 prohibited-list guide explains the sports rules.